Mood stabilizer; thought to act by reducing catecholamine neurotransmitter concentration, through an effect on the Na+/K+ ATPase pump. Effective in the treatment of bipolar disorder. Inhibits GSK-3 in vivo.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 73.89. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||13.53 mL||67.67 mL||135.34 mL|
|5 mM||2.71 mL||13.53 mL||27.07 mL|
|10 mM||1.35 mL||6.77 mL||13.53 mL|
|50 mM||0.27 mL||1.35 mL||2.71 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Lenox and Hahn (2000) Overview of the mechanism of action of lithium in the brain: fifty-year update. J.Clin.Psychiatry 61 5 PMID: 10826655
Gould et al (2004) In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 29 32 PMID: 12942141
If you know of a relevant reference for Lithium carbonate, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Mood stabilizers sodium potassium Na+/K+ ATPase pumps bipolar Glycogen Synthase Kinase 3
Citations for Lithium carbonate
Citations are publications that use Tocris products.
Currently there are no citations for Lithium carbonate. Do you know of a great paper that uses Lithium carbonate from Tocris? If so please let us know.
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.